Childhood melanoma: Update and treatment

International Journal of Dermatology

Volumn 44, Issue 9, 2005, Pages 715-723

  Huynh, Phung M ^a,b   Grant Kels, Jane M ^a,b   Grin, Caron M ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; GANGLIOSIDE; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; HEAT SHOCK PROTEIN; INTERLEUKIN 2; MELACINE; MELAN A; MELANOMA ANTIGEN; MELANOMA VACCINE; MELPHALAN; MONOPHENOL MONOOXYGENASE; PEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR; VINCRISTINE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DRUG DELIVERY SYSTEM; EARLY DIAGNOSIS; HUMAN; MEDICAL DECISION MAKING; MELANOMA; PROGNOSIS; REVIEW; RISK FACTOR; SKIN DEFECT; SKIN PIGMENTATION; SURGICAL TECHNIQUE; TREATMENT PLANNING;

CHILD; HUMANS; MELANOMA; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 24944489281     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2005.02612.x     Document Type: Review

References (85)

1. Hoang M-TR, Eichenfield LF. The rising incidence of melanoma in children and adolescents. Dermatol Nurs 2000; 12: 92-93.
2. Karlsson P, Boeryd B, Sander B, et al. Increasing incidence of cutaneous melanoma in children and adolescents 12-19 years of age in Sweden, 1973-92. Acta Dermatol Venereol 1998; 78:289-292.
3. McWhirter WR, Dobson C, Ring I. Childhood cancer incidence in Australia 1982-1991. Int J Cancer 1996; 65: 34-38.
4. Whiteman D, Valery P, McWhirter W, et al. Incidence of cutaneous childhood melanoma in Queensland, Australia. Int J Cancer 1995; 63: 765-768.
5. Vinceti M, Bergomi M, Borciani N, et al. Rising melanoma incidence in an Italian community from 1986 to 1997. Melanoma Res 1999; 9: 97-103.
6. Berg P, Lindelof B. Differences in malignant melanomas between children and adolescents. Arch Dermatol 1997; 133:295-297.
7. Rao BN, Hayes FA, Pratt CB, et al. Malignant melanoma in children: its management and prognosis. J Pediatr Surg 1990; 25:198-203.
8. Pappo AS, Kaste SC, Rao BN, et al. Childhood melanoma. In: Balch CM, Houghton AN, Sober AJ, et al., eds. Cutaneous Melanoma, Vol. 3. St. Louis, MI: Quality Medical Publishing, Inc., 1998; 175-186.
9. Schmid-Wendtner MH, Berking C, Baumert J, et al. Cutaneous melanoma in childhood and adolescence: an analysis of 36 patients. J Am Acad Dermatol 2002; 46: 874-879.
10. Ceballos PI, Ruiz-Maldonado R, Mihm MC Jr. Melanoma in children. N Engl J Med 1995; 332: 656-662.
11. Prosdocimo T, Smith M, Polack EP. The diagnosis and treatment of childhood melanoma. WV Med J 2002; 98: 149-151.
12. Gibbs P, Moore A, Robinson W, et al. Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population? J Pediatr Hematol Oncol 2000; 22:428-432.
13. Ruiz-Maldonado R, Orozco-Covarrubias M. Malignant melanoma in children: a review. Arch Dermatol 1997; 133: 363-371.
14. McWhirter WR, Dobson C. Childhood melanoma in Australia. World J Surg 1995; 19: 334-336.
15. Richardson SK, Tannous ZS, Mihm MC Jr. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol 2002; 47: 77-90.
16. Schneiderman H, Wu AY, Campbell WA, et al. Congenital melanoma with multiple prenatal metastases. Cancer 1987; 60:1371-1377.
17. Conti EMS, Cercato MC, Gatta G, et al. Childhood melanoma in Europe since 1978: a population-based survival study. Eur J Cancer 2001; 37: 780-784.
18. Fishman C, Mihm MC Jr, Sober AJ. Diagnosis and management of nevi and cutaneous melanoma in infants and children. Clin Dermatol 2002; 20: 44-50.
19. Ruiz-Maldonado R, Tamayo L, Laterza AM, et al. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr 1992; 120: 906-911.
20. Kaplan EN. The risk of malignancy in large congenital nevi. Plast Reconstr Surg 1974; 53: 421-428.
21. Marghoob AA. Congenital melanocytic nevi: evaluation and management. Dermatol Clin 2002; 20: 607-617.
22. Quaba AA, Wallace AF. The incidence of malignant melanoma (0-15 years of age) arising in "large" congenital nevocellular nevi. Plast Reconstr Surg 1986; 78:174-179.
23. Langley RGB, Barnhill RL, Mihm MC Jr, et al. Neoplasms: cutaneous melanoma. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick's Dermatology in General Medicine, Vol. 1. New York: McGraw-Hill, 2003: 917-947.
24. Balch CM, Soong SJ, Milton GW. Changing trends in cutaneous melanoma over a quarter century in Alabama, U.S.A., and New South Wales, Australia. Cancer 1983; 52: 1748-1753.
25. Melnick MK, Urdaneta LF, Al-Jurf AS, et al. Malignant melanoma in childhood and adolescence. Am Surg 1986; 52: 142-147.
26. Tate PS, Ronan SG, Feucht KA, et al. Melanoma in childhood and adolescence: clinical and pathological features of 48 cases. J Pediatr Surg 1993; 28: 217-222.
27. Mehregan AH, Mehregan DA. Malignant melanoma in childhood. Cancer 1993; 71: 4096-4103.
28. Wechsler J, Bastuji-Garin S, Spatz A, et al. Reliability of the histopathologic diagnosis of malignant melanoma in childhood. Arch Dermatol 2002; 138: 615-628.
29. Boddie AW Jr, Smith JL Jr, McBride CM. Malignant melanoma in children and young adults: effect of diagnostic criteria on staging and end results. South Med J 1978; 71: 1074-1078.
30. Chamlin SL, Williams ML. Moles and melanoma. Curr Opin Pediatr 1998; 10: 398-404.
31. Elmwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73: 198-203.
32. Roth ME, Grant-Kels JM, Kuhn K, et al. Melanoma in children. J Am Acad Dermatol 1990; 22: 265-274.
33. Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340: 1341-1348.
34. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum: cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123: 241-250.
35. Tucker MA, Misfeldt D, Coleman N, et al. Cutaneous malignant melanoma after Hodgkin's disease. Ann Int Med 1985; 102:37-41.
36. Penn I. Development of cancer in transplantation patients. Adv Surg 1978; 12: 155-191.
37. Baird EA, McHenry PM, MacKie RM. Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. Br Med J 1992; 305: 799-801.
38. Schaffer JV, Bolognia JL. The clinical spectrum of pigmented lesions. Clin Plast Surg 2000; 27: 391-408.
39. Arons MS, Hurwitz S. Congenital nevocellular nevus: a review of the treatment controversy and a report of 46 cases. Plast Reconstr Surg 1983; 72: 355-365.
40. Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: definition and review of literature. J Am Acad Dermatol 1991; 24:747-755.
41. Garbe C, Buttner P, Weib J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the central malignant melanoma registry of the German Dermatological Society. J Invest Dermatol 1994; 102: 695-699.
42. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987; 17: 459-468.
43. Bataille V, Newton-Bishop JA, Sasieni P, et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case control study. Br J Cancer 1996; 73: 1605-1611.
44. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. J Am Med Assoc 1997; 277: 1439-1444.
45. MacKie RM, Freudenberger T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. Lancet 1989; 2: 487-490.
46. Roush GC, Nordlund JJ, Forget B, et al. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med 1988; 17: 173-279.
47. Grobb JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66: 387-395.
48. Naldi L, Imberti GL, Parazzini F, et al. Pigmentary traits, modalities of sun reaction, history of sunburns, and melanocytic nevi as risk factors for cutaneous malignant melanoma in the Italian population: results of a collaborative case control study. Cancer 2000; 88: 2703-2710.
49. Grulich AE, Bataille V, Swerdlow AJ, et al. Naevi and pigmentary characteristics as risk factors for melanoma in a high risk population: a case-control study in New South Wales. Aust Int J Cancer 1996; 67: 485-491.
50. Greene MH. Dysplastic nevus syndrome. Hosp Pract 1984; 19: 91-108.
51. Salopek TG. The dilemma of the dysplastic nevus. Dermatol Clin 2002; 20: 617-628.
52. Snels DGTM, Hille ETM, Gruis NA, et al. Risk of cutaneous malignant melanoma in patients with nonfamilial atypical nevi from a pigmented lesions clinic. J Am Acad Dermatol 1999; 40: 686-693.
53. Novakovic B, Clark WH Jr, Fears TR, et al. Melanocytic nevi, dysplastic nevi, and malignant melanoma in children from melanoma-prone families. J Am Acad Dermatol 1995; 33.
54. Whiteman D, Milligan A, Welch J, et al. Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Instit 1997; 89:1460.
55. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
56. Trozak DJ, Rowland WD, Hu F. Metastatic malignant melanoma in prepubertal children. Pediatrics 197 5; 55: 591-609.
57. NCCN Melanoma Panel. Melanoma: clinical practice guidelines in oncology. J Natl Comp Cancer Network 2004; 2: 46-60.
58. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of a 2 cm surgical margin for intermediate thickness melanomas (1-4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-269.
59. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97: 1941-1946.
60. Dubois RW, Swetter SM, Atkins M, et al. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alpha-2b in melanoma. Arch Dermatol 2001; 137: 1217-1224.
61. Durrani AJ, Moir GC, Diaz-Cano SJ, et al. Malignant melanoma in an 8-year-old Caribbean girl: diagnostic criteria and utility of sentinel lymph node biopsy. Br J Dermatol 2003; 148: 569-572.
62. Shivers SC, Li W, Lin J, et al. The clinical relevance of molecular staging for melanomas. Recent Results Cancer Res 2001; 158: 187-199.
63. Davis EG, Chao C, McMasters KM. Polymerase chain reaction in the staging of solid tumors. Cancer 2002; 8: 135-143.
64. Hayes FA, Green AA. Malignant melanoma in childhood: clinical course and response to chemotherapy. J Clin Oncol 1984; 2: 1229-1234.
65. Boddie AW Jr, Cangir A. Adjuvant and neoadjuvant chemotherapy with decarbazine in high-risk childhood melanoma. Cancer 1987; 60: 1720-1723.
66. Baas PC, Hoekstra HJ, Koops HS, et al. Hyperthermic isolated regional perfusion in the treatment of extremity melanoma in children and adolescents. Cancer 1989; 63: 199-203.
67. Pratt CB, Palmer MK, Thatcher N, et al. Malignant melanoma in children and adolescents. Cancer 1981; 47: 392-397.
68. Bernstein ID, Wright PW. Immunology and immunotherapy of childhood neoplasia. Pedriatr Clin North Am 1976; 23: 93-109.
69. Morton DL, Eilber FR, Malmgren RA, et al. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970; 68.
70. Eilber FR, Morton DL, Holmes EC, et al. Adjuvant immunotherapy with BCG in treatment of regional-lymph node metastes from malignant melanoma. N Engl J Med 1976; 294: 237-240.
71. Moritz MW, Wallack MK. Survival after malignant melanoma in a black child. Am J Clin Oncol 1984; 7: 545-549.
72. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477-3482.
73. Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 307-319.
74. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
75. Kefford RF. Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol 2002; 14: 358-365.
76. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alpha-2b in high risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 24444-22458.
77. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alpha-2b significantly prolongs relap se-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-2380.
78. Michell MS, Jakowatz J, Harel W, et al. Increased effectiveness of interferon-α2b following active specific immunotherapy for melanoma. J Clin Oncol 1994; 112: 402-411.
79. Vaishampayan U, Abrams J, Darrah D, et al. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon α. Clin Cancer Res 2002; 8: 3696-3701.
80. Wang X-Y, Chen X, Manjili MH, et al. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res 2003; 63: 2553-2560.
81. Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev Vaccines 2003; 2: 369-379
82. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20:4169-4180.
83. Spatz A, Ruiter D, Hardmeier T, et al. Melanoma in childhood: an EORTC-MCG multicenter study on the clinico-pathological aspects. Int J Cancer 1996; 68: 317-324.
84. Saenz NC, Saenz-Badillos J, Busam K, et al. Childhood melanoma survival. Cancer 1999; 85: 750-754.
85. Glusac EJ. Under the microscope: doctors, lawyers, and melanocytic neoplasms. J Cutan Pathol 2003; 30: 287-293.